基因突变和免疫微环境:揭示了与AML预后的联系
ZhongLi Hu1,2, YanLi Yang1, JiaJia Li1
1Department of Haematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, People's Republic of China.
Hematology (Amsterdam, Netherlands)
|April 30, 2024
概括
自然杀手 (NK) 和NK T (NKT) 细胞的比例在急性髓性白血病 (AML) 患者中因基因突变和风险而有所不同. 这些细胞差异与治疗反应和存活率相关,表明AML瘤微环境中的作用.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 是一种异质的血液性恶性瘤.
- 免疫细胞子集,特别是自然杀手 (NK) 和NK T (NKT) 细胞在AML预后中的作用需要进一步阐明.
研究的目的:
- 研究NK和NKT细胞比例差异与急性髓性白血病 (AML) 患者的预后之间的相关性.
- 分析遗传突变和风险分层如何影响AML中的NK和NKT细胞比例.
主要方法:
- 流细胞计用于评估骨髓NK和NKT细胞表达在44名AML患者.
- 下一代测序发现了一些基因突变 (例如,FLT-3-ITD,NPM1,CEBPA,TP53,ASXL1).
- 记录了第一次诱导缓解率和整体存活率,并在不同的遗传和风险组进行了比较.
主要成果:
- 与对照组和FLT3-ITD+/NPM1+组相比,FLT-3-ITD+组显示NK细胞增加和NKT细胞减少.
- CEBPA+组的NKT细胞比TP53+和ASXL1+组的NKT细胞更多.
- 高风险的AML患者比中等风险的患者具有更多的NK细胞和较少的NKT细胞. 诊断时较高的NKT细胞比例与实现缓解相关.
结论:
- 在AML中明显的基因突变通过改变NK和NKT细胞比例来影响瘤微环境.
- 这些免疫细胞的变化与AML患者的治疗反应和整体预后有关.
相关概念视频
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Mutations
82.0K
Overview
82.0K
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K


